# An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

> **NCT04130997** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **TG Therapeutics, Inc.** · enrollment: 1100 (estimated)

## Conditions studied

- Relapsing Multiple Sclerosis (RMS)

## Interventions

- **BIOLOGICAL:** Ublituximab

## Key facts

- **NCT ID:** NCT04130997
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-11-18
- **Primary completion:** 2032-05-31
- **Final completion:** 2032-05-31
- **Target enrollment:** 1100 (ESTIMATED)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04130997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04130997, "An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04130997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*